Mnemo Therapeutics
Kyriaki TSALKITZI has worked in various scientific roles since 2013. Kyriaki began their career as an Intern at Etablissement français du sang (EFS) in 2013, then at Diaclone SAS in 2015. Kyriaki then moved to Institut de Pharmacologie Moléculaire et Cellulaire as a Scientific Associate in 2015. In 2016, they became a Scientific Associate at CIML, then at MIcroenvironment, Cell differentiation, iMmunology And Cancer in 2018. In 2020, they joined Institut Curie as a Scientific Associate, and in 2021, they became a Senior Associate Scientist at Mnemo Therapeutics.
Kyriaki TSALKITZI obtained a Master's degree in Immunology from Aix-Marseille University in 2015 and a Bachelor's degree in Science in Medical Technology from the Technological Educational Institute of Thessaly in 2014.
Mnemo Therapeutics
1 followers
Mnemo Therapeutics is a biotechnology company focused on developing powerful cell therapies that create accessible cures for solid tumors and blood cancers. Its EnfiniT platform, a groundbreaking drug discovery engine, leverages a new class of antigens with greater tumor specificity and a suite of technologies to significantly improve T cell memory, persistence, and sensitivity. The result is dramatic improvement in the body’s immune response to overcome disease. Mnemo is built by a transatlantic team of scientists and biotech leaders united in their mission to create the most powerful immune therapies to deliver accessible cures for all patients in need.